2001Revista de NeurologíaRequires access

¿Son útiles los nuevos fármacos contra la enfermedad de Alzheimer?

Cristóbal Carnero Pardo

Open publisher page 1 citations

Abstract

In recent years several acetylcholinesterase inhibitor drugs have been developed for the treatment of Alzheimer s disease. These are expensive and their usefulness is doubtful. OBJECTIVE. We wish to review the evidence available with regard to the efficacy and effectiveness of the anticholinesterase drugs permitted in Spain. DEVELOPMENT. We review the controlled clinical trials, systematic reviews and meta-analysis published on the anticholinesterases permitted in Spain (tacrine, donepezil and rivastingmine), and also the publications on their effectiveness and efficacy. CONCLUSIONS. The evidence available seems to show that these drugs are effective in producing modest but real cognitive improvement in persons with mild and moderate Alzheimer s disease (Type 1 evidence). Cognitive improvement has also been observed in everyday clinical practice. Use of these drugs may be associated with a reduction in the costs associated with this disease. These drugs are useful and should be used in persons with mild or moderate Alzheimer s disease, without any contra-indication.

About this research paper

What this paper is about

In recent years several acetylcholinesterase inhibitor drugs have been developed for the treatment of Alzheimer s disease. These are expensive and their usefulness is doubtful. OBJECTIVE. We wish to review the evidence available with regard to the efficacy and effectiveness of the anticholinesterase drugs permitted in Spain. DEVELOPMENT. We review the controlled clinical trials, systematic reviews and meta-analysis published on the anticholinesterases permitted in Spain (tacrine, donepezil and rivastingmine), and also the publications on their effectiveness and efficacy. CONCLUSIONS. The evidence available seems to show that these drugs are effective in producing modest but real cognitive improvement in persons with mild and moderate Alzheimer s disease (Type 1 evidence). Cognitive improvement has also been observed in everyday clinical practice. Use of these drugs may be associated with a reduction in the costs associated with this disease. These drugs are useful and should be used in persons with mild or moderate Alzheimer s disease, without any contra-indication.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

In recent years several acetylcholinesterase inhibitor drugs have been developed for the treatment of Alzheimer s disease. These are expensive and their usefulness is doubtful. OBJECTIVE. We wish to review the evidence available with regard to the efficacy and effectiveness of the anticholinesterase drugs permitted in Spain. DEVELOPMENT. We review the controlled clinical trials, systematic reviews and meta-analysis published on the anticholinesterases permitted in Spain (tacrine, donepezil and rivastingmine), and also the publications on their effectiveness and efficacy. CONCLUSIONS. The evidence available seems to show that these drugs are effective in producing modest but real cognitive improvement in persons with mild and moderate Alzheimer s disease (Type 1 evidence). Cognitive improvement has also been observed in everyday clinical practice. Use of these drugs may be associated with a reduction in the costs associated with this disease. These drugs are useful and should be used in persons with mild or moderate Alzheimer s disease, without any contra-indication.

Key concepts: Tacrine, Donepezil, Medicine, Disease, Alzheimer's disease, Clinical trial, Acetylcholinesterase, Intensive care medicine

Related papers

Back to paper searchBrowse research topicsOriginal source
¿Son útiles los nuevos fármacos contra la enfermedad de Alzheimer? — Research Paper | ScholarLens